Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. (Nasdaq: ALT) generates a steady flow of news as a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver, metabolic and cardiometabolic diseases. Most company updates center on its lead investigational medicine, pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), alcohol-associated liver disease (ALD) and obesity.
News coverage of ALT frequently highlights clinical trial milestones. Altimmune issues detailed press releases on the IMPACT Phase 2b trial in MASH, including 24-week and 48-week topline data, changes in non-invasive tests of fibrosis and hepatic inflammation, and AI-based digital pathology analyses of liver biopsies. Additional updates describe progress in the RECLAIM Phase 2 trial in AUD and the RESTORE Phase 2 trial in ALD, including enrollment status and expected timelines for topline results.
Investors and followers of ALT stock also see regulatory and scientific news, such as Fast Track designations for pemvidutide in MASH and AUD, Breakthrough Therapy Designation for MASH, and publication of IMPACT trial data in peer-reviewed journals. Presentations at major medical meetings, including late-breaking oral and poster sessions at The Liver Meeting hosted by the American Association for the Study of Liver Diseases (AASLD), are common subjects of company announcements.
Altimmune’s news flow further includes corporate and financial updates. These range from quarterly financial results and business updates to CEO succession plans, executive appointments, term loan amendments and at-the-market equity offering arrangements disclosed in SEC filings and companion press releases. For anyone tracking ALT, this news page brings together clinical, regulatory, scientific and corporate developments in one place, making it easier to follow how Altimmune’s programs and capital strategy evolve over time.
Altimmune, Inc. (Nasdaq: ALT) reported financial results for Q1 2020, highlighting revenue of $2.2 million down from $3 million year-over-year due to reduced contract billings. R&D expenses surged to $7.2 million compared to $3.2 million in the prior year, driven by IND-enabling studies. The net loss was $3.9 million or ($0.26) per share. Notably, the company commenced preclinical testing of COVID-19 vaccine AdCOVID and plans to launch clinical trials for NasoShield and ALT-801 later in the year, aiming for a data-rich 2020.
Altimmune, a clinical-stage biopharmaceutical company, announced the appointment of Diane Jorkasky, M.D. to its Board of Directors, expanding the board to eight members. Dr. Jorkasky brings extensive experience in drug development across various therapeutic areas. CEO Vipin K. Garg expressed excitement over her contributions to Altimmune's ongoing liver disease and vaccine programs. Dr. Jorkasky emphasized the company's potential impact on public health. Her background includes leadership roles in major pharmaceutical firms, underscoring the breadth of knowledge she brings to the team.